ethyl 5-(pyrazin-2-yl)pentanoate | 479073-63-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 5-(pyrazin-2-yl)pentanoate
• 英文别名: ethyl 5-pyrazin-2-ylpentanoate
• CAS: 479073-63-7
• 化学式: C₁₁H₁₆N₂O₂
• 分子量: 208.26
• InChiKey: YBKZFRYIRWQFAN-UHFFFAOYSA-N

物化性质

• 沸点：
  304.4±32.0 °C(Predicted)
• 密度：
  1.069±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(3-nitrophenylamino)-nicotinaldehyde 、 ethyl 5-(pyrazin-2-yl)pentanoate 、 lithium diisopropyl amide 以to obtain 1-(3-nitrophenyl)-3-[3-(pyrazin-2-yl)propyl]-1,8-naphthyridin-2(1H)-one (yield, 33%)的产率得到1-(3-nitrophenyl)-3-[3-(pyrazin-2-yl)propyl]-1,8-naphthyridin-2(1H)-one
  参考文献：
  名称：

  PDE IV inhibitors

  摘要：

  本发明旨在提供具有强效抗哮喘特性和优良安全性的选择性PDE IV抑制剂。化合物的结构式（1）：其中A为亚甲基，低碳基亚甲基，羰基等，Y为含有一或两个从氮，硫和氧中选择的杂原子的5或6元杂芳基基团，Z为i）融合环，其中任何5或6元杂芳基团融合到苯环上，或ii）苯基，可以是未取代的或可选地取代一个或多个来自硝基，氨基，含氨基氮的基团等的成员所选择的，但当A为亚甲基，Y为从吡咯基，吡啶基等所选择的5或6元杂芳基团，Z为未取代或取代的苯基时，所述苯基上的取代基为氨基或含氨基氮的基团; 或其药学上可接受的盐，具有出色的PDE IV抑制作用，并且作为药物，特别是抗哮喘药物等非常有用。

  公开号：

  US07115623B2
• 作为产物：
  描述：

  2-(dodecylthio)pyrazine 、 ethyl pentanoate,iodozinc(1+) 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 1.0h， 以97%的产率得到ethyl 5-(pyrazin-2-yl)pentanoate
  参考文献：
  名称：

  Palladium-Catalyzed Coupling of N-Heteroaryl Sulfides with Organozinc Reagents

  摘要：

  The palladium-catalyzed cross-coupling of N-heteroaryl sulfides with organozinc reagents was developed. Scope and limitation of the reaction regarding generality of zinc reagents and substrate were also investigated.

  DOI：

  10.3987/com-08-s(f)49

文献信息

• Pde IV inhibitors
  申请人：——

  公开号：US20040176365A1

  公开（公告）日：2004-09-09

  The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): 1 wherein A is methylene, lower alkylmethylene, carbonyl, etc., Y is a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from nitrogen, sulfur and oxygen, Z is i) a fused ring in which any of 5- or 6-membered heteroaryl groups is fused to a benzene ring, or ii) a phenyl group which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of nitro, amino, an amino nitrogen-containing group, etc., provided that when A is methylene, Y is a 5- or 6-membered heteroaryl group selected from the group consisting of pyrrolyl, pyridyl, etc., and Z is a phenyl group which may be unsubstituted or substituted, the substituent on said phenyl group is amino, or an amino nitrogen-containing group; or a pharmaceutically acceptable salt thereof, possesses excellent PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

  这段话的目的是提供具有强效抗哮喘特性和优异安全性的选择性PDE IV抑制剂。式(1)的化合物：其中A是亚甲基，低碳基亚甲基，羰基等，Y是含有氮、硫和氧中的一种或两种杂原子的5-或6成员杂芳基团，Z是i）融合环，其中任何5-或6成员杂芳基团融合到苯环中，或ii）苯基，可以是未取代或可选地取代一个或多个来自硝基，氨基，含氨基氮的基团等的成员，但当A是亚甲基时，Y是从吡咯基，吡啶基等中选择的5-或6成员杂芳基团，Z是未取代或取代的苯基时，所述苯基上的取代基是氨基或含氨基氮的基团；或其药学上可接受的盐，具有优异的PDE IV抑制作用，是一种有用的药物，首选是抗哮喘药物等。
• PDE IV INHIBITORS
  申请人：Grelan Pharmaceutical Co., Ltd.

  公开号：EP1403270A1

  公开（公告）日：2004-03-31

  The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): wherein A is methylene, lower alkylmethylene, carbonyl, etc., Y is a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from nitrogen, sulfur and oxygen, Z is i) a fused ring in which any of 5- or 6-membered heteroaryl groups is fused to a benzene ring, or ii) a phenyl group which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of nitro, amino, an amino nitrogen-containing group, etc., provided that when A is methylene, Y is a 5- or 6-membered heteroaryl group selected from the group consisting of pyrrolyl, pyridyl, etc., and Z is a phenyl group which may be unsubstituted or substituted, the substituent on said phenyl group is amino, or an amino nitrogen-containing group; or a pharmaceutically acceptable salt thereof, possesses excellent PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

  目的是提供选择性 PDE IV 抑制剂，这种抑制剂具有强效的抗哮喘特性和极佳的安全性。一种式（1）的化合物： 其中 A 是亚甲基、低级烷基亚甲基、羰基等；Y 是 5 或 6 元杂芳基，含有一个或两个选自氮、硫和氧的杂原子；Z 是 i) 融合环，其中任何 5 或 6 元杂芳基与苯环融合；或 ii) 苯基，可以是未取代的，也可以是被一个或多个选自硝基、氨基、含氮氨基等组成的组的成员任选取代的、条件是当 A 为亚甲基，Y 为选自吡咯基、吡啶基等组成的组的 5 或 6 元杂芳基，Z 为未取代或取代的苯基时，所述苯基上的取代基为氨基或含氮氨基；或其药学上可接受的盐，具有优异的 PDE IV 抑制作用，可用作药物，最好是抗哮喘药物等。
• US7115623B2
  申请人：——

  公开号：US7115623B2

  公开（公告）日：2006-10-03
• Palladium-Catalyzed Coupling of N-Heteroaryl Sulfides with Organozinc Reagents
  作者：Tohru Fukuyama、Hidetoshi Tokuyama、Takahiro Koshiba、Tohru Miyazaki

  DOI：10.3987/com-08-s(f)49

  日期：——

  The palladium-catalyzed cross-coupling of N-heteroaryl sulfides with organozinc reagents was developed. Scope and limitation of the reaction regarding generality of zinc reagents and substrate were also investigated.
• PDE IV inhibitors
  申请人：Aska Pharmaceuticals Co., Ltd.

  公开号：US07115623B2

  公开（公告）日：2006-10-03

  The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): wherein A is methylene, lower alkylmethylene, carbonyl, etc., Y is a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from nitrogen, sulfur and oxygen, Z is i) a fused ring in which any of 5- or 6-membered heteroaryl groups is fused to a benzene ring, or ii) a phenyl group which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of nitro, amino, an amino nitrogen-containing group, etc., provided that when A is methylene, Y is a 5- or 6-membered heteroaryl group selected from the group consisting of pyrrolyl, pyridyl, etc., and Z is a phenyl group which may be unsubstituted or substituted, the substituent on said phenyl group is amino, or an amino nitrogen-containing group; or a pharmaceutically acceptable salt thereof, possesses excellent PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.

  本发明旨在提供具有强效抗哮喘特性和优良安全性的选择性PDE IV抑制剂。化合物的结构式（1）：其中A为亚甲基，低碳基亚甲基，羰基等，Y为含有一或两个从氮，硫和氧中选择的杂原子的5或6元杂芳基基团，Z为i）融合环，其中任何5或6元杂芳基团融合到苯环上，或ii）苯基，可以是未取代的或可选地取代一个或多个来自硝基，氨基，含氨基氮的基团等的成员所选择的，但当A为亚甲基，Y为从吡咯基，吡啶基等所选择的5或6元杂芳基团，Z为未取代或取代的苯基时，所述苯基上的取代基为氨基或含氨基氮的基团; 或其药学上可接受的盐，具有出色的PDE IV抑制作用，并且作为药物，特别是抗哮喘药物等非常有用。